Merus to Present at Upcoming Investor Conferences
Merus N.V. (Nasdaq: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced upcoming presentations at two major investor conferences. CEO Bill Lundberg will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 9:40 a.m. ET and the Jefferies Global Healthcare Conference on June 4 at 3:10 p.m. ET. The presentations will be available via webcast on the company's Investors page, with recordings accessible for a limited time afterward.
Merus N.V. (Nasdaq: MRUS), un'azienda specializzata in oncologia e nello sviluppo di anticorpi multispecifici innovativi e coniugati anticorpo-farmaco (Biclonics®, Triclonics® e ADClonics®), ha annunciato la partecipazione a due importanti conferenze per investitori. Il CEO Bill Lundberg presenterà al William Blair 45th Annual Growth Stock Conference il 3 giugno alle 9:40 ET e al Jefferies Global Healthcare Conference il 4 giugno alle 15:10 ET. Le presentazioni saranno disponibili in webcast sulla pagina Investitori dell'azienda, con le registrazioni accessibili per un periodo limitato successivamente.
Merus N.V. (Nasdaq: MRUS), una compañía especializada en oncología y en el desarrollo de anticuerpos multispecíficos innovadores y conjugados anticuerpo-fármaco (Biclonics®, Triclonics® y ADClonics®), ha anunciado presentaciones próximas en dos importantes conferencias para inversores. El CEO Bill Lundberg presentará en la William Blair 45th Annual Growth Stock Conference el 3 de junio a las 9:40 a.m. ET y en la Jefferies Global Healthcare Conference el 4 de junio a las 3:10 p.m. ET. Las presentaciones estarán disponibles vía webcast en la página de Inversores de la compañía, con grabaciones accesibles por tiempo limitado posteriormente.
Merus N.V. (Nasdaq: MRUS)는 종양학에 특화된 회사로 혁신적인 다중특이성 항체 및 항체-약물 접합체(Biclonics®, Triclonics® 및 ADClonics®)를 개발하고 있으며, 두 주요 투자자 컨퍼런스에서 발표를 진행할 예정입니다. CEO 빌 런드버그는 6월 3일 오전 9시 40분(동부시간)에 William Blair 45th Annual Growth Stock Conference에서, 6월 4일 오후 3시 10분(동부시간)에 Jefferies Global Healthcare Conference에서 발표할 예정입니다. 발표 내용은 회사 투자자 페이지에서 웹캐스트로 제공되며, 이후 일정 기간 동안 녹화본도 이용할 수 있습니다.
Merus N.V. (Nasdaq : MRUS), une entreprise spécialisée en oncologie et développant des anticorps multispecifics innovants ainsi que des conjugués anticorps-médicament (Biclonics®, Triclonics® et ADClonics®), a annoncé ses prochaines présentations lors de deux grandes conférences pour investisseurs. Le PDG Bill Lundberg interviendra lors de la William Blair 45th Annual Growth Stock Conference le 3 juin à 9h40 ET et lors de la Jefferies Global Healthcare Conference le 4 juin à 15h10 ET. Les présentations seront accessibles en webcast sur la page Investisseurs de la société, avec les enregistrements disponibles pendant une durée limitée par la suite.
Merus N.V. (Nasdaq: MRUS), ein auf Onkologie spezialisiertes Unternehmen, das innovative multispezifische Antikörper und Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) entwickelt, hat bevorstehende Präsentationen auf zwei wichtigen Investorenkonferenzen angekündigt. CEO Bill Lundberg wird am William Blair 45th Annual Growth Stock Conference am 3. Juni um 9:40 Uhr ET und am Jefferies Global Healthcare Conference am 4. Juni um 15:10 Uhr ET präsentieren. Die Präsentationen werden per Webcast auf der Investorenseite des Unternehmens verfügbar sein, wobei Aufzeichnungen im Anschluss für eine begrenzte Zeit abrufbar sind.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the following investor conferences:
- William Blair 45th Annual Growth Stock Conference: Tuesday, June 3 at 8:40 a.m. CT/9:40 a.m. ET
- Jefferies Global Healthcare Conference: Wednesday, June 4 at 3:10 p.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. The archived presentations will also be available there for a limited time after the event.
About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, LinkedIn and Bluesky.
Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.
Investor and Media Inquiries: Sherri Spear Merus N.V. SVP Investor Relations and Strategic Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. Director IR/Corp Comms 617-230-4165 k.farren@merus.nl
FAQ
When is Merus (MRUS) presenting at the William Blair Conference in 2025?
What time is Merus (MRUS) presenting at the Jefferies Global Healthcare Conference?
Who will be presenting at the upcoming Merus (MRUS) investor conferences?
Where can investors watch Merus (MRUS) conference presentations?
